2/14/18
3 years of SDF & SM-ART
Jeremy Horst DDS,PhD UCSF
disclosures
My research is funded by gifts & grants from:
Chan-Zuckerburg BioHub
Advantage Silver Arrest
Howard Hughes Medical Institute
National Institutes of Health
Jeremy Horst
https://sites.google.com/site/
JeremyAHorst/SanGabriel201802
1 2/14/18
3 year outcome – severely fragile 3 to 7 year old
1 year 3 years
No excavation SDF + GIC
2 years
Outline _ 1. SDF – what is it? 2. SDF adoption 3. SDF clinical evidence 4. SDF clinical use 5. SDF mechanisms 6. SDF treatment failure 7. SDF x-ray follow up 8. SMART
2 2/14/18
SDF - what is it?
Colorless liquid 25% silver: antimicrobial 8% ammonia: solvent 5% fluoride: remineralization
SDF vs SN + FV
SDF SN + FV 25% silver 16% silver 8% ammonia 9% nitrate 5% fluoride 2.5% fluoride > effect data > safety data
BOTH are safe & effective.
SDF - what does it do?
- Arrests dental caries
- Prevents dental caries • directly & indirectly
- Decreases dentin hypersensitivity
3 2/14/18
How do you use it?
Accessible 1. Isolate with cotton. Arrested cavities cavity. 2. Air dry. after 1 year 3. Apply with microbrush.
Where did this come from?
• Silver Nitrate used globally for >1000 years. – Caries arrest case series & protocols in 1800s. – 1891: 87 of 142 treated lesions were arrested. – Founding fathers of dentistry had protocols.
• AgF used in Japan for ~900 years. – Cosmetic blackening of teeth – Known to prevent caries.
+ • NH3 added in 1960s = SDF. – Approved & monitored by Japan.
• Available in Japan, Australia, Brazil, Argentina, Cuba, China since 1980s or before…
Rosenblatt et al, J Dent Res 2009
4 2/14/18
SDF is now available in the U.S.
~60¢/drop D1354 caries arrest CDT code active January 2016.
FDA clearance = hypersensitivity. Off label use = caries treatment. This is the same as BREAKTHROUGH THERAPY fluoride varnish.
Outline _ 1. SDF – what is it? 2. SDF adoption 3. SDF clinical evidence 4. SDF clinical use 5. SDF mechanisms 6. SDF treatment failure 7. SDF x-ray follow up 8. SMART
What do parents think about SDF? SDF
uncoop. semi- coop. coop
n=33 Tesoriero & Lee 2016 boys girls
5 2/14/18
Oregon: 30 2-5 year olds, 102 cavities, SDF 30s+, FV @3 mon, 100 stopped, no ∝ application time.
Esthetics? SSC or SDF
Dr. Jason Hirsch
6 2/14/18
NIDCR, January 2017
sales of SDF bottles per dentist
bottles.per.dentist 50% 30% 20% 10% 5% 3% 2% 1%
SDF is here to stay.
January 2016
Periodontics and Oral-Systemic Relationships Atypical Presentation of Zoster Leadership Trajectories of U.S. Dentists JournaCALIFORNIA DENTAL ASSOCIATION
7 2/14/18
Outline _ 1. SDF – what is it? 2. SDF adoption 3. SDF clinical evidence 4. SDF clinical use 5. SDF mechanisms 6. SDF treatment failure 7. SDF x-ray follow up 8. SMART inkids Arrest Caries Caries
10 0% Llodra et al., 2005 373 6 year olds 50 % SDF q6mon control: 2.5 new lesions (only applied to lesions) 100% SDF q1year Liu et al., 2012 50 % Sealant once 482 9.1 year olds NaF q6 mon control: 4.6 new lesions 100% SDF q1year Chu et al., 2002 exc SDF q1 year 308 3-5 year olds 50 % exc N aF q3mon control: 1.6 new lesions NaF q3 mon (only applied to lesions) revented caries 100% p SDF once Monse et al., 2012 50 % GIC se alant once 708 6-8 year olds control: 0.44 new lesions 0% 0.5 1 1.5 2 2.5 3 time (years)
8 2/14/18
Older adults 100%# SDF#q1year# Li et al., 2016 50%# SDF,#KI#q1year# 67 72 year olds 1.9 lesions at start control## 100%#0%# SDF#q1year# Zhang et al., 2013 Arrest 50%# +#OHI#q6mon# 227 60-89 year olds control## 0.91 lesions at start 0%# 0.5# 1# 1.5# 2# 2.5# 3#
100%# SDF#q1year# Tan et al., 2010 50%# NaF#q3mon# 203 79 year olds Chlorhex#q3mon# control: 2.5 new lesions 100%#0%# Zhang et al., 2013 SDF#q1year# 50%# 227 60-89 year olds +#OHI#q6mon# control: 1.3 new lesions Prevention 0%# 0.5# 1# 1.5# 2# 2.5# 3# time (years)
Learned from clinical trials?
• 12 RCTs with 1,816 patients tx SDF = safe. • 9 on caries arrest. 80-90% arrest with 2/year application. 40-80% arrest with 1/year application.
• 6 on caries prevention (3 overlap). 70-80% prevention in kids by application only to lesions. 25-70% prevention, outperforms everything by far.
Stopping Cavities Trial purpose: Safety & Arrest Effectiveness
n arrested (SD) 95% CI adverse events flu, nausea, SDF 30 .72 (.38) .55 to .85 redness, spot diarrhea x 2, placebo 36 .05 (.18) .00 to .16 tummy ache, toothache + diarrhea
Advantage, UW, UCSF
9 2/14/18
Microbiology by “sequencing”
∆ species after SDF
6 unc Tannerella Gemella morbillorum Roseburia intestinalis Proteus mirabilis No unc Lachnospiraceae Clostridium piliforme 4 decreases 10 −log p 2
FDR<.01 FDR<.05 0 logFC|>2 −8 −4 0 4 8 ∆ relative abundance SDF log ( ) 2 ∆ relative abundance placebo
Trial Summary